| Summary: | 碩士 === 中國醫藥大學 === 生物統計研究所碩士班 === 100 === Background:
Alendronate drugs play protective roles in fracture. However, the interaction between Alendronate and re-fracture and the therapeutic dosage to prevent re-fracture remains unclear.
Methods:
We conducted a population-based, retrospective case-control cohort study of 4,860 patients in Taiwan. Case cohorts (with Alendronate drugs) and control cohorts (without Alendronate drugs) were selected from patients with a primary diagnosis of fracture. Controls were matched by age, gender, index day and fracture history at a ratio of 1 : 4 (case : controls) during the same time period. Odds ratios (ORs) were calculated to determine the risk of re-fracture by using conditional logistic regression model.
Results:
The odds ratio of re-fracture in the “without Alendronate” control cohort was significantly higher than the “with Alendronate” case cohort between 1 day and 3 years, OR = 0.71 (95% CI = 0.56-0.91) for doseage 1 day to 182 days, and OR=0.26 (95% CI = 0.56-0.91) for doseage more than 182 day.
Conclusions:
Our results provided evidence to support the viewpoint that Alendronate may be a feasible method for the prevention of re-fracture.
|
|---|
